ANALYTICAL/QUALITY ARTICLES
-
![cars driving on a bridge-GettyImages-1167795076]( "The RNA Synthesis Spectrum: Between Solid-Phase Roots & A Hybrid Enzymatic Future")
The RNA Synthesis Spectrum: Between Solid-Phase Roots & A Hybrid Enzymatic FutureThere were two additional takeaways I had following my conversation with Kuchimanchi, each of which depicts where there still exists quite a bit of dynamism for an industry which can claim an “established” manufacturing paradigm.
-
![2 spotlights shining on stage-GettyImages-2215898262]( "Oligos Step Into The Spotlight: A Growing Force In Genetic Medicine")
Oligos Step Into The Spotlight: A Growing Force In Genetic MedicineOligonucleotide therapeutics are experiencing a new wave of momentum. As the science evolves and the market opportunity expands, the landscape is poised for continued growth and diversification.
-
![Athletic Jump-GettyImages-130409478]( "Beyond Solid-Phase Synthesis: The Momentum of Oligonucleotide Manufacturing")
Beyond Solid-Phase Synthesis: The Momentum of Oligonucleotide ManufacturingOverall, there were three main takeaways I gleaned from our conversation that suggest the oligo sector, though more established than its mRNA cousin, is not comfortable with the status quo and is actively trying to grow beyond the limits of its current manufacturing paradigm. Here in part 1, we’ll start with my number one takeaway, which also comes equipped with a bit of history as to how we find ourselves at our current juncture.
-
![DNA strands, genetic biotechnology, gene cell-GettyImages-2154784301]( "Inside Arbor Biotech's In Vivo Gene Therapy Approach")
Inside Arbor Biotech's In Vivo Gene Therapy ApproachFollowing recent news about first-in-human testing, two executives discuss the science and manufacturing strategy for the company's lead candidate, ABO-101.
-
![GettyImages-2152639905-five-5]( "5 Takeaways From The MHRA mRNA Guidance")
5 Takeaways From The MHRA mRNA GuidanceHaving read and reread the MHRA's guidance on personalized mRNA cancer immunotherapies, the following five takeaways will function somewhat as a mind-meld, combining a few of my own thoughts/takeaways with those of the MHRA.
-
![GettyImages-1481419356-archaeologist-ancient-inscription]( "Ancient Molecule, Modern Medicine: The Science, Strategy, & Stakeholders Behind tRNA Therapeutics")
Ancient Molecule, Modern Medicine: The Science, Strategy, & Stakeholders Behind tRNA TherapeuticsAs we all know well, “unearthing” our molecules’ potential poses numerous technical and business-related challenges for young biotech companies. Here, Werner and I continue our conversation, unpacking some of these internal and external challenges the company is navigating as it strives to bring tRNA to the commercial market.
ANALYTICAL/QUALITY VIDEOS
As the panelists of this Advancing RNA LIVE discussion argue, there are several big limitations we face in implementing QBD today for RNA development.
In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?
In this Advancing RNA Live segment, several speakers raise concerns about the industry's ability to accurately measure impurities, particularly dsRNA, arguing that current analytics are insufficient, especially for high-dose therapeutics.
NxGen Technology delivers a scalable means to perform the critical particle formation step in a nanomedicine development process.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2148124393 DNA]( "A Risk-Based Approach To Plasmid DNA And mRNA Process Development")
A Risk-Based Approach To Plasmid DNA And mRNA Process DevelopmentBalancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
![GettyImages-2160715091 lab analysis]( "Targeted LC-MS/MS Detection Of Lipid Impurities In Lipid Nanoparticles")
Targeted LC-MS/MS Detection Of Lipid Impurities In Lipid NanoparticlesLearn about an HPLC-MS/MS method for detecting lipid impurities in lipid nanoparticles (LNPs) and why it is critical for quality control of LNP-based drug delivery systems.
-
![Scientist lab cell and gene dna GettyImages-1305079941]( "Ultra-Sensitive Assay For Anti-Sense Oligonucleotide Quantification")
Ultra-Sensitive Assay For Anti-Sense Oligonucleotide QuantificationLearn about a new level in sensitivity for challenging analytes in matrix that opens doors for accurate bioanalysis and metabolism studies with specificity not achievable with orthogonal methods.
-
![GettyImages-1437856375-lnp-lipid-nanoparticle]( "Nanomedicine Modalities Find Path To Clinic Through Analytics")
Nanomedicine Modalities Find Path To Clinic Through AnalyticsLipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.
-
![GettyImages-1145414430_Oligonucleotides]( "Selection And Evaluation Of Hybridization Capture Probes For LC/MS Analysis Of Oligonucleotides")
Selection And Evaluation Of Hybridization Capture Probes For LC/MS Analysis Of OligonucleotidesTo overcome challenges in oligonucleotide LC/MS bioanalysis, consider optimizing probe design by evaluating alternative chemistries like PNA for improved recovery and chromatographic performance.
-
![GettyImages-1475620245 lab, assay]( "Structural Characterization Of RNA And Detection Of RNA-Ligand Binding")
Structural Characterization Of RNA And Detection Of RNA-Ligand BindingDelve into the intricacies of riboswitch behavior and ligand interactions and gain valuable insights into gene regulation and potential therapeutic targets.
-
![GettyImages-1183908006 bioanalysis]( "The Future Of Small And Large Molecule Bioanalytics")
The Future Of Small And Large Molecule BioanalyticsLearn how innovative, emerging technologies are revolutionizing the field of bioanalytics and drug development.
